BioAge and Novartis seek drug targets for ageing-related diseases
BioAge will receive an upfront payment and research funding of up to $20m.
Drug Development
Novo Holdings completes Catalent acquisition for $16.5bn
Gilead and Terray link to develop small-molecule therapies
Bavarian Nordic signs mpox vax deal with Serum Institute of India
Conduit and Sarborg link to optimise AI drug development
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia
Relation-GSK to drive fibrotic and osteoarthritis developments
Dr Myles Greenberg becomes president and CEO of InCarda Therapeutics
